Advertisement

Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series

Published:December 20, 2018DOI:https://doi.org/10.1016/j.ajog.2018.12.021

      Background

      As part of transition, transmasculine persons often use testosterone gender-affirming hormone therapy; however, there is limited data on its long-term effects. The impact of exogenous testosterone on uterine pathology remains unclear. While testosterone achieves amenorrhea in the majority of this population, persistence of abnormal uterine bleeding can be difficult to manage. Excess androgens in cisgender females are associated with pathologic uterine processes such as polycystic ovary syndrome, endometrial hyperplasia, or cancer. There are no guidelines for management of abnormal uterine bleeding or endometrial surveillance in this population.

      Objective

      The aim of this study was to describe the characteristics of uterine pathology after the initiation of testosterone in transmasculine persons.

      Materials and Methods

      A retrospective, multicenter case series was performed. Uterine pathology reports of transmasculine persons who received testosterone and subsequently underwent hysterectomy were reviewed. The endometrial phase and endometrial thickness were recorded.

      Results

      A total of 94 subjects met search criteria. The mean age of participants was 30 ± 8.6 years, and the mean interval from initiation of testosterone to hysterectomy was 36.7 ± 36.6 months. Active endometrium was found in the majority of patients (n = 65; 69.1%). One patient had complex hyperplasia without atypia. There were no cases of endometrial cancer.

      Conclusion

      Despite amenorrhea in the majority of transmasculine persons on testosterone, endometrial activity persists with predominantly proliferative endometrium on histopathology. Individualized counseling for abnormal uterine bleeding is encouraged in this patient population.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Perrone A.M.
        • Cerpolini S.
        • Maria Salfi N.C.
        • et al.
        Effect of long term testosterone administration on the endometrium of female-to-male (FtM) transsexuals.
        J Sex Med. 2009; 6: 3193-3200
        • Grynberg M.
        • Fanchin R.
        • Dubost G.
        • et al.
        Histology of the genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population.
        Repro Biomed Online. 2010; 20: 553-558
        • Loverro G.
        • Resta L.
        • Dellino M.
        • et al.
        Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals.
        Taiwan J Obstet Gynecol. 2016; 55: 686-691
        • Khalifa M.A.
        • Toyama A.
        • Klein M.E.
        • Santiago V.
        Histologic features of hysterectomy specimens from female-male transgender individuals.
        Int J Gynecol Pathol. 2018; ([Epub ahead of print])
        • Fearnley E.J.
        • Marquart L.
        • Spurdle A.B.
        • Weinstein P.
        • Webb P.M.
        Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study.
        Cancer Causes Control. 2010; 21: 2303-2308
        • Allen N.E.
        • Key T.J.
        • Dossus L.
        • et al.
        Endogenous sex hormones and endometrial cancer risk in the European Investigation into Cancer and Nutrition (EPIC).
        Endocr Relat Cancer. 2008; 15: 485-497
        • Tuckerman E.M.
        • Okon M.A.
        • Laird S.M.
        Do androgens have a direct effect on endometrial function? An in vitro study.
        Fertil Steril. 2000; 74: 771-779
        • Harris P.A.
        • Taylor R.
        • Thielke R.
        • Payne J.
        • Gonzalez N.
        • Conde J.G.
        Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inform. 2009; 42: 377-381
        • Whitaker L.
        • Critchley H.O.
        Abnormal uterine bleeding.
        Best Pract Res Clin Obstet Gynaecol. 2016; 34: 54-65
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics 2018.
        Ca Cancer J Clin. 2018; 68: 7-30
        • Chandra V.
        • Kim J.J.
        • Benbrook D.M.
        • Dwivedi A.
        • Rai R.
        Therapeutic options for management of endometrial hyperplasia.
        J Gynecol Oncol. 2016; 27: e8
        • Jurgensen A.
        • Mettler L.
        • Volkov N.I.
        • Parwaresch R.
        Proliferative activity of the endometrium throughout the menstrual cycle in infertile women with and without endometriosis.
        Fertil Steril. 1996; 66: 369-375
        • Enriori C.L.
        • Reforzo-Membrives J.
        Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review.
        Gynecol Oncol. 1984; 17: 1-21
        • Institute of Medicine
        The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding.
        National Academies Press, Washington, DC2011
        • Cote M.L.
        • Alhajj T.
        • Ruterbusch J.J.
        • Bernstein L.
        • Brinton L.A.
        • Blot W.J.
        Risk factors for endometrial cancer risk in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium.
        Cancer Causes Control. 2015; 26: 287-296
        • Elbers J.M.
        • Giltay E.J.
        • Teerlink T.
        • et al.
        Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects.
        Clin Endocrinol. 2003; 58: 562-571
        • Urban R.
        • Teng N.N.H.
        • Kapp D.S.
        Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance.
        Am J Obstet Gynecol. 2011; 204: e9-e12
      1. World Professional Association for Transgender Health (WPATH). Standards of care for the health of transsexual, transgender, and gender nonconforming people, 7th Version. WPATH 2012. Available at: http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351. Accessed March 6, 2018.

        • Hembree W.C.
        • Cohen-Kettenis P.
        • Gooren L.
        • et al.
        Endocrine treatment of gender dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2017; 102: 1-35
        • American College of Obstetrics and Gynecology
        Diagnosis of abnormal uterine bleeding in reproductive-aged women. ACOG Practice Bulletin No. 128.
        Obstet Gynecol. 2012; 120: 197-206
        • Carswell J.M.
        • Roberts S.A.
        Induction and maintenance of amenorrhea in transmasculine and nonbinary adolescents.
        Transgender Health. 2017; 2: 195-201
        • Deligdisch L.
        Hormonal pathology of the endometrium.
        Mod Pathol. 2000; 13: 285-294
        • Amezcua C.A.
        • Lu J.J.
        • Felix J.C.
        • Stanczyk F.Z.
        • Zheng W.
        Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
        Gynecol Oncol. 2000; 79: 169-176
        • American College of Obstetrics and Gynecology
        Long-acting reversible contraception: implants and intrauterine devices. ACOG Practice Bulletin No. 186.
        Obstet Gynecol. 2017; 130: e251-e269
        • Light A.D.
        • Obedin-Maliver J.
        • Sevelius J.M.
        • Kerns J.L.
        Transgender men who experienced pregnancy after female-to-male gender transitioning.
        Obstet Gynecol. 2014; 124: 1120-1127
        • Pavone M.E.
        • Bulun S.E.
        The use of aromatase inhibitors for ovulation induction and superovulation.
        J Clin Endocrinol Met. 2013; 98: 1838-1844
        • Meriggiola M.C.
        • Armillotta F.
        • Costantino A.
        • et al.
        Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
        J Sex Med. 2008; 5: 2442-2453
        • DeCensi A.
        • Sun Z.
        • Guerrieri-Gonzaga A.
        • et al.
        Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen, and their sequences.
        Breast Cancer Res Treat. 2014; 144: 321-329
        • Coleman R.E.
        • Body J.J.
        • Gralow J.R.
        • Lipton A.
        Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
        Cancer Treat Rev. 2008; 34: S31-S42
        • American College of Obstetrics and Gynecology
        The role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. ACOG Committee Opinion Number 734. May 2018.
        Obstet Gynecol. 2018; 131: e124-e129
        • Pelusi C.
        • Costantino A.
        • Martelli V.
        Effects of three different testosterone formulations in female-to-male transsexual persons.
        J Sex Med. 2014; 11: 3002-3011
        • Coleman E.
        • Bockting W.
        • Botzer M.
        • et al.
        Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7.
        Int J Transgenderism. 2012; 13: 165-232